Did you know #Stargardtdisease affects about 44,000 people in the U.S. and there is no treatment option for this blindness disease? For more information about Ocugen’s Phase 2/3 OCU410ST clinical trial, email clinical.request@ocugen.com. #VisionHealth #OCU410ST

Exciting news! Ocugen CEO Dr. Shankar Musunuri is now on X! Follow @drsmusunuri for updates on biotechnology innovation, leadership, and how we’re shaping the future of patient care across the world through our novel modifier gene therapies. #Biotech #Leadership #Ocugen

We’re advancing clinical research in Stargardt disease! Ocugen is now enrolling U.S. patients for our Phase 2/3 OCU410ST-101/301 trial, starting at age 3. Learn more: NCT05956626 | clinical.request@ocugen.com #ClinicalTrials #StargardtDisease #GeneTherapy

Our CMO, Dr. Huma Qamar, will present at the Advances in Pediatric Retina Course on Sept 19, 2025, highlighting progress in pediatric retinal disease diagnosis & management. More info: https://t.co/BhgwgIkV81 #APR2025 #PediatricRetina #Ophthalmology #HealthcareInnovation

Hear from Evan, a retinitis pigmentosa (RP) patient who participated in the OCU400 Expanded Access Program (EAP). To learn more about the OCU400 EAP or Phase 3 liMeliGhT clinical trial, email clinical.request@ocugen.com or call 484-237-3390. #RetinitisPigmentosa

Recently, @MollyBOfficial spoke with Dr. Lejla Vajzovic about how Ocugen’s Phase 3 LiMeliGhT clinical trial is providing hope to all RP patients—regardless of mutation or stage of the disease. Learn more: clinical.request@ocugen.com | 484-237-3390 #RetinitisPigmentosa

We are aiming for 3 BLAs in 3 years, a bold move toward advancing gene therapies for blindness diseases. Learn more about our vision in this @GENbio feature. 🔗 https://t.co/pTVEx2EBAF #Ocugen #GeneTherapy #Biotech

Inspired by voices like @MollyBOfficial’s, we’re advancing science to potentially provide a gene therapy to all RP patients. Ocugen’s Phase 3 OCU400 liMeliGhT trial is currently enrolling. 📩 clinical.request@ocugen.com 📞 484-237-3390 #OCU400 #RP #GeneTherapy #ClinicalTrials

Big news! We’ve dosed the first patient in our Phase 2/3 GARDian3 trial for #Stargardtdisease (OCU410ST). With no approved treatment today, this huge milestone brings us one step closer to helping patients with this blindness disease. Details: https://t.co/o2QljoagWa

300,000 people in the U.S. & Europe are living with retinitis pigmentosa. Our Phase 3 #OCU400 liMeliGhT trial is the only gene-agnostic therapy in development. Now enrolling. Learn more: NCT06388200 | clinical.request@ocugen.com #GeneTherapy #RP #ClinicalTrials

Ocugen is breaking barriers in clinical trials with a gene-agnostic approach that has the potential to restore vision for those with inherited retinal diseases. Learn more from CMO @drhumaqamar's interview with @ClinicalLeader1: https://t.co/RIPmRJD2SJ. #IRDs #Biotech

BIG NEWS! The @US_FDA has granted Rare Pediatric Disease Designation to OCU410ST for the treatment of Stargardt disease. A big step forward in fighting inherited vision loss. 👁️ Read more here: https://t.co/9i7KTGFYCe. #Ocugen #GeneTherapy #FDA

It’s #StargardtAwarenessWeek. This IRD causes vision loss and affects 100K people in the U.S. & Europe. We’re developing OCU410ST, a gene therapy candidate aimed at slowing or stopping progression. 🔗 https://t.co/y7nw8gMNuO. #StargardtDisease #GeneTherapy #VisionResearch

Today, we announced our business and financial results for Q1 2025. Hear a recap from our Chairman, CEO, and Co-founder, Dr. Shankar Musunuri and read the full press release here: https://t.co/PmIE0B4RXp. #GeneTherapy

Proud to present today at #RetinaWorldCongress in Ft. Lauderdale, where our CMO Dr. Huma Qamar presented on Ocugen’s modifier gene therapy platform and served alongside notable retinal surgeons and industry peers during a panel discussion. #GeneTherapy #Ophthalmology

Hear from Ocugen Chairman, CEO and Co-Founder, Dr. Shankar Musunuri about Ocugen’s dedication to providing a novel modifier gene therapy for people with retinitis pigmentosa (RP) that can potentially stabilize or reverse the disease. #ClinicalTrials #RetinitisPigmentosa

Next week, Dr. Shankar Musunuri and Jyothy Pillai will participate in a fireside chat during Chardan’s virtual conference focused on the evolving regulatory landscape for biotechnology. A replay will be available on the Ocugen website following the conference. #GeneTherapy

Happy Easter to those who celebrate. Wishing you a day filled with joy and a season of rejuvenation. #Easter2025

Introducing a series from Ocugen leadership that highlights the work we are doing to lead the way in gene therapies for blindness diseases. In this first interview with CMO, Dr. Huma Q. hear more about the promise OCU410ST holds to address Stargardt disease. #IRD

Listen to Chairman, CEO and Co-founder, Dr. Shankar Musunuri discuss Ocugen’s novel approach to developing gene therapies for blindness diseases on the latest episode of the Empowered Patient Podcast with Karen Jagoda: https://t.co/kH3xsUxrNG